KCP-330-020

KCP-330-020

Brief description of study

The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each 42 day cycle until disease progression, intolerability, consent withdrawal or unblinding in Phase 2, 3, and open-label portion of the study.

Detailed description of study

A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLEBLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Liposarcoma
  • Age: Between 18 Years - 99 Years
  • Gender: All
Updated on 31 Jan 2020. Study ID: 825937

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center